In the last trading session, 4.53 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was 0.82. Most recently the company’s share price was $0.17, and it changed around -$0.02 or -11.58% from the last close, which brings the market valuation of the company to $8.19M. BTAI currently trades at a discount to its 52-week high of $3.96, offering almost -2229.41% off that amount. The share price’s 52-week low was $0.18, which indicates that the current value has fallen by an impressive -5.88% since then. We note from BioXcel Therapeutics Inc’s average daily trading volume that its 10-day average is 0.18 million shares, with the 3-month average coming to 1.81 million.
BioXcel Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.25. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended BTAI as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Instantly BTAI has showed a red trend with a performance of -11.58% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.3300 on recent trading dayincreased the stock’s daily price by 48.48%. The company’s shares are currently down -55.87% year-to-date, but still down -49.39% over the last five days. On the other hand, BioXcel Therapeutics Inc (NASDAQ:BTAI) is -64.99% down in the 30-day period. We can see from the shorts that 0.35 million shares have been sold at a short interest cover period of 0.93 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 83.0% from its current value. Analyst projections state that BTAI is forecast to be at a low of $1 and a high of $1.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.97%. BioXcel Therapeutics Inc earnings are expected to increase by 74.51% in 2025, but the outlook is positive 50.29% per year for the next five years.
BTAI Dividends
BioXcel Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 20.06% of BioXcel Therapeutics Inc shares, and 8.76% of them are in the hands of institutional investors. The stock currently has a share float of 10.96%. BioXcel Therapeutics Inc stock is held by 72.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 9.6767% of the shares, which is about 2.99 million shares worth $3.82 million.
FMR LLC, with 7.1439% or 2.21 million shares worth $2.82 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
